{"id":"CHEMBL1020","canonicalSmiles":"Cc1ccc(C(=O)c2ccc(CC(=O)O)n2C)cc1","inchiKey":"UPSPUYADGBWSHF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"TOLMETIN","yearOfFirstApproval":1976,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["MCN-2559","Tolectin","Tolmetin"],"crossReferences":{"DailyMed":["tolmetin%20sodium"],"Wikipedia":["Tolmetin"],"drugbank":["DB00500"],"chEBI":["71941"]},"childChemblIds":["CHEMBL1556918","CHEMBL1200613","CHEMBL1437585"],"linkedTargets":{"rows":["ENSG00000073756","ENSG00000095303"],"count":2},"linkedDiseases":{"rows":["HP_0002829","EFO_0000685","HP_0003326","MONDO_0005178","EFO_0005755"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1976 and has 5 approved indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1081312","canonicalSmiles":"Nc1ncnc2c1c(-c1cnc3[nH]ccc3c1)nn2C1CCCC1","inchiKey":"NVRXTLZYXZNATH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1081312","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["103904782"],"drugbank":["DB08052"],"chEBI":["50915"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1136","canonicalSmiles":"CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C","inchiKey":"LJVAJPDWBABPEJ-PNUFFHFMSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"TELITHROMYCIN","yearOfFirstApproval":2004,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ketek"],"synonyms":["HMR 3647","HMR-3647","Ketek","Levviax","NSC-758940","Telithromycin"],"crossReferences":{"DailyMed":["telithromycin"],"PubChem":["144205007","144205756"],"Wikipedia":["Telithromycin"],"drugbank":["DB00976"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2004 and has 3 approved and 7 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL114500","canonicalSmiles":"COc1ccnc(NC2CCN(C(=O)c3ccc(C#N)cc3)CC2)c1","inchiKey":"SZUVGMCKKLJAFX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AR-C133057XX","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AR-C133057XX"],"crossReferences":{"drugbank":["DB07002"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1200332","canonicalSmiles":"CNCCCC1c2ccccc2C=Cc2ccccc21.Cl","inchiKey":"OGQDIIKRQRZXJH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"PROTRIPTYLINE HYDROCHLORIDE","yearOfFirstApproval":1967,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL668","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Concordin-10","Concordin-5","Protriptyline hydrochloride","Vivactil"],"synonyms":["MK-240","NSC-169912","Protriptyline hcl","Protriptyline hydrochloride"],"crossReferences":{"DailyMed":["protriptyline%20hydrochloride"],"PubChem":["144203795","170465077","50106858","50106859","56422215","855990"],"chEBI":["8598"]},"linkedTargets":{"rows":["ENSG00000108576","ENSG00000103546"],"count":2},"linkedDiseases":{"rows":["MONDO_0002050"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1967 and is indicated for depressive disorder. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1200468","canonicalSmiles":"CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC","inchiKey":"JXSJBGJIGXNWCI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MALATHION","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cythion","Derbac-m","Malathion","Organoderm","Ovide","Prioderm","Quellada-m","Suleo-m"],"synonyms":["8059HC","ENT 17,034","ENT-17034","Malathion","NSC-6524","OVIDE"],"crossReferences":{"DailyMed":["malathion"],"PubChem":["144214009","170465311","17389839","26753130","26753131","50105655"],"Wikipedia":["Malathion"],"drugbank":["DB00772"],"chEBI":["6651"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1982 and is indicated for parasitic infection and has 1 investigational indication."}
{"id":"CHEMBL1200609","canonicalSmiles":"CS(=O)(=O)O.Fc1ccc([C@@H]2CCNC[C@H]2COc2ccc3c(c2)OCO3)cc1","inchiKey":"SHIJTGJXUHTGGZ-RVXRQPKJSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"PAROXETINE MESYLATE","yearOfFirstApproval":2003,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL490","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Brisdelle","Pexeva"],"synonyms":["Mesafem","PO-T.MES","POT.MES","Paroxetine mesilate","Paroxetine mesylate","Paroxetine methanesulfonate","Paroxetine methanesulphonate"],"crossReferences":{"DailyMed":["paroxetine%20mesylate"]},"linkedTargets":{"rows":["ENSG00000108576"],"count":1},"linkedDiseases":{"rows":["HP_0031217","EFO_0003922"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2003 and has 2 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1200987","canonicalSmiles":"CCCCc1ncc(/C=C(\\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1.CS(=O)(=O)O","inchiKey":"DJSLTDBPKHORNY-XMMWENQYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"EPROSARTAN MESYLATE","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL813","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Eprosartan mesylate","Teveten"],"synonyms":["Eprosartan mesilate","Eprosartan mesylate","Eprosartan monomethanesulfonate","SK&F 108566-J","SK&F-108566-J"],"crossReferences":{"DailyMed":["eprosartan%20mesylate"],"PubChem":["144205739","170465071"],"chEBI":["48409"]},"linkedTargets":{"rows":["ENSG00000144891"],"count":1},"linkedDiseases":{"rows":["MONDO_0001134","EFO_0000537"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for hypertension and has 1 investigational indication. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1201295","canonicalSmiles":"Cc1ccc(C(=O)Oc2ccc(C(O)CNC(C)(C)C)cc2OC(=O)c2ccc(C)cc2)cc1","inchiKey":"FZGVEKPRDOIXJY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BITOLTEROL","yearOfFirstApproval":1984,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Bitolterol"],"crossReferences":{"PubChem":["170465239"],"Wikipedia":["Bitolterol"],"drugbank":["DB00901"],"chEBI":["3133"]},"childChemblIds":["CHEMBL1200405"],"linkedTargets":{"rows":["ENSG00000169252"],"count":1},"linkedDiseases":{"rows":["HP_0006536"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1984 and is indicated for airway obstruction."}
{"id":"CHEMBL1201645","drugType":"Unknown","blackBoxWarning":false,"name":"INTRINSIC FACTOR","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Castle's intrinsic factor","Intrinsic factor","Intrinsic factor concentrate","Intrinsic factor pork","Intrinsic factor, concentrate"],"description":"Unknown drug with a maximum clinical trial phase of IV and is indicated for anemia (phenotype)."}
{"id":"CHEMBL1201782","canonicalSmiles":"CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.C[C@@H](O[C@H]1OCCN(Cc2nn(P(=O)(O)O)c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1","inchiKey":"VRQHBYGYXDWZDL-OOZCZQCLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FOSAPREPITANT DIMEGLUMINE","yearOfFirstApproval":2008,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1199324","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Emend","Fosaprepitant dimeglumine"],"synonyms":["Fosaprepitant (as dimeglumine)","Fosaprepitant dimeglumine","Fosaprepitant meglumine","MK-0517"],"crossReferences":{"DailyMed":["fosaprepitant%20dimeglumine"],"chEBI":["64311"]},"linkedTargets":{"rows":["ENSG00000115353"],"count":1},"linkedDiseases":{"rows":["EFO_0006911","HP_0002017","EFO_0004888","EFO_0000691","EFO_0000311"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 4 approved and 2 investigational indications."}
{"id":"CHEMBL1213460","canonicalSmiles":"CCOC(=O)C1N=C(c2ccccc2F)c2cc(Cl)ccc2NC1=O","inchiKey":"CUCHJCMWNFEYOM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ETHYL LOFLAZEPATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ethyl loflazepate","Meilax"],"crossReferences":{"Wikipedia":["Ethyl_loflazepate"],"drugbank":["DB01545"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1230575","canonicalSmiles":"CC(C)=CCC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC/C(C)=C/CC1=C(C)C(=O)c2ccccc2C1=O","inchiKey":"RAKQPZMEYJZGPI-LJWNYQGCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MENAQUINONE 7","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Menakinon 7","Menaquinone 7","Menaquinone k7","Menaquinone-7","Vitamin k2(35)","Vitamin mk 7"],"crossReferences":{"drugbank":["DB13075"],"chEBI":["44245"]},"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL1232702","canonicalSmiles":"COC(=O)C1CCN(C(=O)c2ccc(N(C)Cc3cnc4nc(N)nc(N)c4n3)cc2)CC1","inchiKey":"UKCFUFHREWUXJJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1232702","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07765"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1234619","canonicalSmiles":"N[C@@H](Cc1ccc2ccccc2c1)C(=O)O","inchiKey":"JPZXHKDZASGCLU-LBPRGKRZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1234619","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01766"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1235556","canonicalSmiles":"O=C(O)Cn1cc(Cc2nc3c(F)c(F)cc(F)c3s2)c2cccnc21","inchiKey":"IEVFQDJUDLCOQY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1235556","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08449"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1236475","canonicalSmiles":"O=C1N[C@H](O)CCN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O","inchiKey":"UCKYOOZPSJFJIZ-FMDGEEDCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TETRAHYDROURIDINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-112907","NSC-112907-D","Tetrahydrouridine","U-23284"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 8 investigational indications."}
{"id":"CHEMBL1237044","canonicalSmiles":"COc1cccc(C2(O)CCCCC2CN(C)C)c1","inchiKey":"TVYLLZQTGLZFBW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"TRAMADOL","yearOfFirstApproval":1995,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Amanda","CG-315E","E-265","ETS-6103","ETS6103","Tramadol","U-26255A","Ultracet","Ultram"],"crossReferences":{"DailyMed":["tramadol%20hydrochloride"],"chEBI":["75722"]},"childChemblIds":["CHEMBL1237065"],"linkedTargets":{"rows":["ENSG00000112038"],"count":1},"linkedDiseases":{"rows":["EFO_1001139","EFO_0005687","MONDO_0002009","MONDO_0007254","EFO_0003964","EFO_1000783","HP_0030834","EFO_0004253","EFO_0009093","EFO_1000652","EFO_0004616","HP_0003419","EFO_0003877","EFO_1001250","EFO_0005762","EFO_0000685","EFO_0004210","HP_0012532","EFO_0010072","EFO_0003898","EFO_0001358","HP_0003418","EFO_0003843","EFO_0000311","HP_0002027","EFO_0000546","EFO_0003890","EFO_1000391","EFO_0005800","HP_0030833","HP_0100607","EFO_0005611","MONDO_0002258","MONDO_0005178","HP_0000023","EFO_0000181","EFO_0003833"],"count":37},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1995 and has 3 approved and 18 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1237099","canonicalSmiles":"COc1cc(CC2c3c(cc(OC)c(OC)c3OC)CC[N+]2(C)CCCOC(=O)CCC(=O)OCCC[N+]2(C)CCc3cc(OC)c(OC)c(OC)c3C2Cc2cc(OC)c(OC)c(OC)c2)cc(OC)c1OC.[Cl-].[Cl-]","inchiKey":"APADFLLAXHIMFU-UHFFFAOYSA-L","drugType":"Small molecule","blackBoxWarning":false,"name":"DOXACURIUM CHLORIDE","yearOfFirstApproval":1991,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1237123","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Nuromax"],"synonyms":["BW A938U DICHLORIDE","BW-A938U","Doxacurium chloride","Doxacurium chloride, meso-","Meso doxacurium chloride"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1991."}
{"id":"CHEMBL1257040","canonicalSmiles":"CN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1.Cl.Cl","inchiKey":"BXDAOUXDMHXPDI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"TRIFLUOPERAZINE HYDROCHLORIDE","yearOfFirstApproval":1959,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL422","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Stelazine","Trifluoperazine hydrochloride"],"synonyms":["NSC-757369","Trifluoperazine HCl","Trifluoperazine dihydrochloride","Trifluoperazine hcl","Trifluoperazine hydrochloride","Trifluoperazine maleate"],"crossReferences":{"DailyMed":["trifluoperazine%20hydrochloride"],"PubChem":["144203568","170465265","26747694","26747695","50107169"],"chEBI":["9710"]},"linkedTargets":{"rows":["ENSG00000069696","ENSG00000149295","ENSG00000102468","ENSG00000151577","ENSG00000147246"],"count":5},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0006788","EFO_0000677"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1959 and has 3 approved indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1257051","canonicalSmiles":"Cn1nnc(-c2ccc(-c3ccc(N4C[C@H](CO)OC4=O)cc3F)cn2)n1","inchiKey":"XFALPSLJIHVRKE-GFCCVEGCSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TEDIZOLID","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Sivextro"],"synonyms":["TR-700","Tedizolid","Torezolid"],"crossReferences":{"Wikipedia":["Torezolid"],"drugbank":["DB14569"],"chEBI":["82717"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for bacterial disease and has 1 investigational indication."}
{"id":"CHEMBL126589","canonicalSmiles":"Nc1nc2cc(O)ccc2[nH]1","inchiKey":"FNSYWIPPPFVBAV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL126589","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03729"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1267","canonicalSmiles":"CC(O)c1ccc(CCOc2ccc(CC3SC(=O)NC3=O)cc2)nc1","inchiKey":"OXVFDZYQLGRLCD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LERIGLITAZONE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Hydroxypioglitazone","Leriglitazone","MIN-102","Min-102"],"crossReferences":{"drugbank":["DB15021"],"chEBI":["82937"]},"childChemblIds":["CHEMBL4298170"],"linkedTargets":{"rows":["ENSG00000132170"],"count":1},"linkedDiseases":{"rows":["Orphanet_68356","Orphanet_95"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1540","canonicalSmiles":"Nc1nc(O)c2ncn(CCC(CO)CO)c2n1","inchiKey":"JNTOCHDNEULJHD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PENCICLOVIR","yearOfFirstApproval":1996,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Denavir","Fenistil","Vectavir"],"synonyms":["BRL-39123","NSC-759624","Penciclovir"],"crossReferences":{"DailyMed":["penciclovir"],"PubChem":["144205801","170464955"],"Wikipedia":["Penciclovir"],"drugbank":["DB00299"],"chEBI":["7956"]},"childChemblIds":["CHEMBL2079793"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1996 and is indicated for viral disease and herpes labialis."}
{"id":"CHEMBL167731","canonicalSmiles":"NCCNc1ccc(NCCN)c2c1C(=O)c1ccncc1C2=O","inchiKey":"PEZPMAYDXJQYRV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PIXANTRONE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["BBR 2778","BBR-2778","Pixantrone"],"crossReferences":{"PubChem":["225144373"],"Wikipedia":["Pixantrone"],"drugbank":["DB06193"]},"childChemblIds":["CHEMBL537394","CHEMBL2103844"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for neoplasm and has 9 investigational indications."}
{"id":"CHEMBL1743018","drugType":"Antibody","blackBoxWarning":false,"name":"FICLATUZUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AV 299","AV-299","Ficlatuzumab","SCH 900105","SCH-900105"],"linkedTargets":{"rows":["ENSG00000019991"],"count":1},"linkedDiseases":{"rows":["EFO_0002618","EFO_0000222","EFO_0001378","EFO_0000707","EFO_0000519","EFO_0000181","EFO_0003060"],"count":7},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL174391","canonicalSmiles":"C1CCN(C2CCNCC2)CC1","inchiKey":"QDVBKXJMLILLLB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"[1,4']Bipiperidinyl","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["[1,4']Bipiperidinyl"],"crossReferences":{"drugbank":["DB03056"],"chEBI":["40117"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL184041","canonicalSmiles":"Cc1cc(-c2c3ccccc3c(Br)c3sc(C)c(C)c23)cc(C)c1O[C@H](Cc1ccccc1)C(=O)O","inchiKey":"FONCZICQWCUXEB-RUZDIDTESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ERTIPROTAFIB","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ertiprotafib","PTP-112"],"crossReferences":{"drugbank":["DB06521"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL18442","canonicalSmiles":"c1cc(CN2CCCNCCNCCCNCC2)ccc1CN1CCCNCCNCCCNCC1","inchiKey":"YIQPUIGJQJDJOS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PLERIXAFOR","yearOfFirstApproval":2008,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Mozobil"],"synonyms":["AMD 3100","AMD3100","JM 3100","Plerixafor","Plerixafor hydrochloride","Plerixafor octahydrochloride","SID 791"],"crossReferences":{"DailyMed":["plerixafor"],"PubChem":["174007494","29217477"],"Wikipedia":["Plerixafor"],"drugbank":["DB06809"]},"childChemblIds":["CHEMBL1788331","CHEMBL2311028","CHEMBL554014","CHEMBL2088494","CHEMBL2373140","CHEMBL2311089"],"linkedTargets":{"rows":["ENSG00000121966"],"count":1},"linkedDiseases":{"rows":["Orphanet_84","EFO_0003086","Orphanet_232","MONDO_0003783","EFO_1001465","EFO_1001469","EFO_0005952","EFO_1001311","EFO_0000565","MONDO_0015760","EFO_1001459","MONDO_0001475","EFO_1001996","MONDO_0019460","EFO_0000183","EFO_0000400","EFO_0000717","Orphanet_379","EFO_0000198","EFO_0002618","EFO_0006859","EFO_0000220","MONDO_0019457","EFO_0000403","EFO_0000222","MONDO_0000870","MONDO_0044881","EFO_0004599","EFO_1000654","EFO_0000095","MONDO_0005147","EFO_0000574","EFO_0001378","MONDO_0018906","EFO_0000691"],"count":35},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2008 and has 3 approved and 30 investigational indications."}
{"id":"CHEMBL1901620","canonicalSmiles":"CCCCC[C@H](O)/C=C/C1=C(C/C=C\\CCCC(=O)O)C(=O)CC1","inchiKey":"PRFXRIUZNKLRHM-HKVRTXJWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1901620","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["26754807"],"drugbank":["DB02304"],"chEBI":["28099"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL191886","canonicalSmiles":"Cc1ncc2c(c1O)COC2c1ccc(Cl)cc1","inchiKey":"CVKNDPRBJVBDSS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CICLETANINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["(+/-)BN-1270","BN-1270","Cicletanine","Cycletanide","WIN 90,000","WIN-90000"],"crossReferences":{"Wikipedia":["Cicletanine"],"drugbank":["DB12766"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1963681","canonicalSmiles":"COc1ccc(C/N=c2\\[nH]c(N3CCC[C@H]3CO)ncc2C(=O)NCc2ncccn2)cc1Cl","inchiKey":"WEAJZXNPAWBCOA-INIZCTEOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AVANAFIL","yearOfFirstApproval":2011,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Spedra","Stendra"],"synonyms":["Avanafil","TA-1790"],"crossReferences":{"DailyMed":["avanafil"],"PubChem":["165222624"],"Wikipedia":["Avanafil"],"drugbank":["DB06237"],"chEBI":["66876"]},"linkedTargets":{"rows":["ENSG00000138735"],"count":1},"linkedDiseases":{"rows":["EFO_0003086","EFO_0004234"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and is indicated for erectile dysfunction and has 1 investigational indication."}
{"id":"CHEMBL1981292","canonicalSmiles":"CC(C)CC(NC(=O)CNC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(Cc1c[nH]cn1)NC(=O)C1CCC(=O)N1)C(=O)NC(CCCNC(=N)N)C(=O)N1CCCC1C(=O)NCC(N)=O","inchiKey":"XLXSAKCOAKORKW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1981292","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["124893762"],"drugbank":["DB00644"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2028661","canonicalSmiles":"CCOc1nc2cccc(C(=O)OCc3oc(=O)oc3C)c2n1Cc1ccc(-c2ccccc2-c2noc(=O)[nH]2)cc1","inchiKey":"QJFSABGVXDWMIW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"AZILSARTAN MEDOXOMIL","yearOfFirstApproval":2011,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Edarbi"],"synonyms":["AR-14","Azilsartan medoxomil","Ipreziv","TAK 491","TAK-491"],"crossReferences":{"DailyMed":["azilsartan%20kamedoxomil"],"drugbank":["DB08822"],"chEBI":["68845"]},"childChemblIds":["CHEMBL2103795"],"linkedTargets":{"rows":["ENSG00000144891"],"count":1},"linkedDiseases":{"rows":["MONDO_0001134","EFO_0000712","EFO_0000319","EFO_0000537"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2011 and has 3 approved and 2 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2079130","canonicalSmiles":"CNCc1cc(-c2ccccc2F)n(S(=O)(=O)c2cccnc2)c1","inchiKey":"BFDBKMOZYNOTPK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VONOPRAZAN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Takecab","Vocinti"],"synonyms":["TAK-438","Vonoprazan"],"crossReferences":{"drugbank":["DB11739"]},"childChemblIds":["CHEMBL2064032"],"linkedTargets":{"rows":["ENSG00000105675","ENSG00000186009"],"count":2},"linkedDiseases":{"rows":["EFO_0003948","EFO_0009454","HP_0004398","EFO_0004607","EFO_1000961","EFO_1001095"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL2104753","canonicalSmiles":"COc1ccc2nc(COc3ccc(CC4SC(=O)NC4=O)cc3)n(C)c2c1","inchiKey":"XMSXOLDPMGMWTH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RIVOGLITAZONE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CS-011","DE-101","R 106056","R-106056","Rivoglitazone"],"crossReferences":{"drugbank":["DB09200"]},"childChemblIds":["CHEMBL3526906","CHEMBL3527103","CHEMBL3526905"],"linkedTargets":{"rows":["ENSG00000132170"],"count":1},"linkedDiseases":{"rows":["EFO_1000906","MONDO_0005148"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2105740","canonicalSmiles":"Cc1cc2c(cc1CC(=O)c1sccc1S(=O)(=O)[N-]c1onc(C)c1Cl)OCO2.[Na+]","inchiKey":"MDTNUYUCUYPIHE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SITAXENTAN SODIUM","yearOfFirstApproval":2006,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL282724","hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["European Union"],"classes":["Hepatotoxicity"],"year":2010},"tradeNames":["Thelin"],"synonyms":["Sitaxentan sodium","Sitaxsentan sodium","Sitaxsentan sodium salt","TBC-11251 SODIUM","TBC-11251NA","TBC-11251Z"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2006. It was withdrawn in European Union  in 2010 due to Hepatotoxicity."}
{"id":"CHEMBL2105857","canonicalSmiles":"CC[C@@]1(OC(=O)[C@@H](NC(=O)[C@H](Cc2c[nH]cn2)NC(=S)Nc2ccc(O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](OC)[C@@H]3O)cc2)C(C)C)C(=O)OCc2c1cc1n(c2=O)Cc2cc3ccccc3nc2-1","inchiKey":"SLOJCSGNHWIKIG-JNYZSSQASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AFELETECAN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Afeletecan"],"childChemblIds":["CHEMBL4297664"],"linkedTargets":{"rows":["ENSG00000198900"],"count":1},"linkedDiseases":{"rows":["EFO_0000681"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2106236","canonicalSmiles":"COc1ccc2c(c1)CC[C@@H]1[C@@H]2CC[C@]2(C)[C@H](O)[C@H](O)C[C@@H]12","inchiKey":"UHQGCIIQUZBJAE-RRQVMCLOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EPIMESTROL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Epimestrol","NSC-55975","ORG 817","ORG-817"],"crossReferences":{"drugbank":["DB13386"],"chEBI":["34738"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2106483","canonicalSmiles":"CCOc1ccccc1OCC1CNCCO1.Cl","inchiKey":"HJOCKFVCMLCPTP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"VILOXAZINE HYDROCHLORIDE","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL306700","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Qelbree","Vivalan"],"synonyms":["ICI 58,834","ICI-58834","SPN-812","Spn-812","Viloxazine hcl","Viloxazine hydrochloride"],"crossReferences":{"PubChem":["170466300"]},"linkedTargets":{"rows":["ENSG00000103546"],"count":1},"linkedDiseases":{"rows":["EFO_0003888"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2021 and is indicated for attention deficit hyperactivity disorder. This drug has a black box warning from the FDA."}
{"id":"CHEMBL2106822","canonicalSmiles":"CCN(CC)Cc1nccn1-c1ccc([N+](=O)[O-])cc1C(=O)c1ccccc1Cl","inchiKey":"WZGBZLHGOVJDET-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NIZOFENONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Nizofenone","Nizofenone fumarate"],"crossReferences":{"PubChem":["144206537","170466022"],"drugbank":["DB13546"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2106840","canonicalSmiles":"CCCOCCOC(=O)C1=C(C)NC(C)=C(C(=O)OCCOCCC)C1c1cccc([N+](=O)[O-])c1","inchiKey":"VZWXXKDFACOXNT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NILUDIPINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BAY A 7168","Niludipine"],"crossReferences":{"drugbank":["DB09240"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2107357","canonicalSmiles":"CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc21.O=P(O)(O)O.O=P(O)(O)O","inchiKey":"ONDPWWDPQDCQNJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MOTESANIB DIPHOSPHATE","maximumClinicalTrialPhase":3,"parentId":"CHEMBL572881","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AMG 706","Motesanib diphosphate","Motesanib phosphate"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 17 investigational indications."}
{"id":"CHEMBL2108228","drugType":"Antibody","blackBoxWarning":false,"name":"BECTUMOMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Lympho scan","Lymphoscan"],"synonyms":["Bectumomab","IMMU-LL2","Technetium tc 99m bectumomab"],"description":"Antibody drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL2108387","drugType":"Unknown","blackBoxWarning":false,"name":"LANOLIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Adeps lanae","Anhydrous lanolin","Emery 1600","Eucerite","Lanolin","Lanolin - anhydrous","Lanolin anhydrous","Lanolin, anhydrous","Lanolin, purified","Lanolin,anhydrous","Lanolin,anhydrous liquid","Ovis aries","Purified lanolin","Suintine","Wool fat","Wool grease","Wool wax"],"description":"Unknown drug with a maximum clinical trial phase of III."}
{"id":"CHEMBL2108401","drugType":"Antibody","blackBoxWarning":false,"name":"ENLIMOMAB PEGOL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BIRR-1","Enlimomab pegol","R6.5"],"description":"Antibody drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL2108621","drugType":"Antibody","blackBoxWarning":false,"name":"MAPATUMUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["HGS-1012","HGS-ETR1","HGS1012","Mapatumumab","TRAIL-R 1MAB","TRAIL-R1 MAB","TRM-1","TRM-1 HGS-ETR1"],"linkedTargets":{"rows":["ENSG00000104689"],"count":1},"linkedDiseases":{"rows":["MONDO_0002974","EFO_0000182","EFO_0001378","EFO_0005952","EFO_0003060"],"count":5},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL2109283","drugType":"Antibody","blackBoxWarning":false,"name":"BICIROMAB BRALLOBARBITAL","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Fibriscint"],"synonyms":["Biciromab brallobarbital","T2G1S"],"description":"Antibody drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2109309","drugType":"Antibody","blackBoxWarning":false,"name":"RHIGM12B7","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["RHIGM12B7","Rhigm12b7"],"linkedTargets":{"rows":["ENSG00000197646"],"count":1},"linkedDiseases":{"rows":["EFO_0000389"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2109496","drugType":"Antibody","blackBoxWarning":false,"name":"MLN-01","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MLN-01"],"description":"Antibody drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2109624","drugType":"Antibody","blackBoxWarning":false,"name":"CAPLACIZUMAB","yearOfFirstApproval":2019,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cablivi"],"synonyms":["ALX-0081","Caplacizumab","Caplacizumab-yhdp"],"crossReferences":{"DailyMed":["caplacizumab-yhdp"]},"linkedTargets":{"rows":["ENSG00000110799"],"count":1},"linkedDiseases":{"rows":["HP_0004419","MONDO_0018896","MONDO_0019740"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2019 and has 3 approved indications."}
{"id":"CHEMBL2110553","drugType":"Small molecule","blackBoxWarning":false,"name":"GALLIUM CITRATE","yearOfFirstApproval":1976,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Citric acid, gallium salt (1:1)","Gallium citrate","NSC-15011"],"childChemblIds":["CHEMBL1200994"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1976 and has 1 investigational indication."}
{"id":"CHEMBL2110771","canonicalSmiles":"CC[N+](C)(C)CCC(C(N)=O)(c1ccccc1)c1ccccc1","inchiKey":"KFZMXOLSYABOSE-UHFFFAOYSA-O","drugType":"Small molecule","blackBoxWarning":false,"name":"AMBUTONIUM","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Ambutonium cation","Ambutonium ion"],"childChemblIds":["CHEMBL2105972"],"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL212616","canonicalSmiles":"CC(C)c1cc(C(C)C)c(S(=O)(=O)N[C@@H](Cc2cccc(C(=N)N)c2)C(=O)N2CCN(C(=O)CCN)CC2)c(C(C)C)c1","inchiKey":"WATXEHGLYJKXOF-NDEPHWFRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL212616","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB04172"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2151437","canonicalSmiles":"c1cnc2c(c1)C[C@@]1(CN3CCC1CC3)O2","inchiKey":"OCKIPDMKGPYYJS-ZDUSSCGKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AZD0328","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZD-0328","AZD0328","Azd 0328","Azd-0328","Azd0328"],"crossReferences":{"drugbank":["DB12145"]},"linkedTargets":{"rows":["ENSG00000175344"],"count":1},"linkedDiseases":{"rows":["MONDO_0005090","MONDO_0004975"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL236086","canonicalSmiles":"COCc1cc(O)cc2c1O[C@@H](c1ccc(O)cc1)[C@H]1CCC[C@@H]21","inchiKey":"RHQLNMNKTIOREN-AOIWGVFYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL236086","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08020"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2376648","canonicalSmiles":"C[C@@H](Oc1cc(C(=O)Nc2ccc(C(=O)N3CCN(C)CC3)cc2)nnc1N)c1c(Cl)ccc(F)c1Cl","inchiKey":"ONPGOSVDVDPBCY-CQSZACIVSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"X-396","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["X-396"],"crossReferences":{"drugbank":["DB13104"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2397450","canonicalSmiles":"OC[C@H]1O[C@@H](c2cc(Cc3cc4cccccc-4c3)ccc2O)[C@H](O)[C@@H](O)[C@@H]1O","inchiKey":"AGJJCLBOHJQGFA-ZQGJOIPISA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"YM-543","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"childChemblIds":["CHEMBL4297452"],"linkedTargets":{"rows":["ENSG00000140675"],"count":1},"linkedDiseases":{"rows":["MONDO_0005148"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2401865","canonicalSmiles":"CC[C@H](C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)[C@@H](C)O)C(=O)N[C@@H](C)C(=O)O","inchiKey":"PXZWGQLGAKCNKD-DPNMSELWSA-N","drugType":"Protein","blackBoxWarning":false,"name":"OXYNTOMODULIN","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Oxyntomodulin"],"description":"Protein drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL245807","canonicalSmiles":"O=C1Nc2ccccc2C1(c1ccc(O)cc1)c1ccc(O)cc1","inchiKey":"SJDACOMXKWHBOW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OXYPHENISATINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["Australia"," Germany"," France"," United Kingdom"," United States"],"classes":["Hepatotoxicity"],"year":1971},"tradeNames":[],"synonyms":["Isaphen","NSC-59814","Oxyphenisatin","Oxyphenisatine"],"crossReferences":{"PubChem":["144212248","170466393"],"Wikipedia":["Oxyphenisatine"],"drugbank":["DB04823"]},"description":"Small molecule drug with a maximum clinical trial phase of IV and is indicated for constipation. It was withdrawn in Australia,  Germany,  France,  United Kingdom and  United States initially in 1971 due to Hepatotoxicity."}
{"id":"CHEMBL252128","canonicalSmiles":"CCNC(=O)c1cn2ncnc(Nc3cc(C(=O)NOC)ccc3C)c2c1C","inchiKey":"ZZTMFGIGOADCFX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL252128","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB06940"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL256563","canonicalSmiles":"C[C@](C#N)(COc1cc(C#N)ccc1C(F)(F)F)NC(=O)c1ccc(SC(F)(F)F)cc1","inchiKey":"WTERNLDOAPYGJD-SFHVURJKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MONEPANTEL","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Monepantel"],"crossReferences":{"chEBI":["78621"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3137342","drugType":"Antibody","blackBoxWarning":true,"name":"DINUTUXIMAB","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Ch14.18","Dinutuximab","Dinutuximab beta","ch14.18-UTC"],"crossReferences":{"DailyMed":["dinutuximab"],"DrugCentral":["4948"]},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2015 and is indicated for neuroblastoma and neoplasm and has 3 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL315818","canonicalSmiles":"NCC(CC(=O)O)c1ccccc1","inchiKey":"DAFOCGYVTAOKAJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PHENIBUT","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Dl-4-amino-3-phenylbutanoic acid","Fenibut","Phenibut","Phenigamma","Phenygam","Phgaba"],"crossReferences":{"Wikipedia":["Phenibut"],"drugbank":["DB13455"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL316388","canonicalSmiles":"C[C@H]1CN(C(=O)c2ccc(C#N)cc2)[C@H](C)CN1C(=O)[C@@](C)(O)C(F)(F)F","inchiKey":"IWFSHKKFDSWNLZ-BWACUDIHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL316388","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08608"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3182477","canonicalSmiles":"CCOP(=S)(OCC)OP(=S)(OCC)OCC","inchiKey":"XIUROWKZWPIAIB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SULFOTEP","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["144208954","144213452"],"drugbank":["DB11497"],"chEBI":["38945"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3187503","canonicalSmiles":"CC(C)c1noc(N2CCC(COc3ccc(-c4ccc(S(C)(=O)=O)cc4)nc3)CC2)n1","inchiKey":"AYJRTVVIBJSSKN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GSK-1292263","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GSK-1292263","GSK-1292263A","GSK-263A","GSK1292263","Gsk 1292263","Gsk-1292263","Gsk1292263"],"crossReferences":{"PubChem":["174006808"],"drugbank":["DB12627"]},"linkedTargets":{"rows":["ENSG00000147262"],"count":1},"linkedDiseases":{"rows":["MONDO_0005148","Orphanet_309005"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL319467","canonicalSmiles":"NS(=O)(=O)c1ccc(Nc2nc(OCC3CCCCC3)c3nc[nH]c3n2)cc1","inchiKey":"OWXORKPNCHJYOF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NU-6102","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NU-6102"],"crossReferences":{"drugbank":["DB07126"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL32749","canonicalSmiles":"COc1cc(/C=C/C(=O)O)ccc1O","inchiKey":"KSEBMYQBYZTDHS-HWKANZROSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FERULATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ferulic acid"],"crossReferences":{"PubChem":["26748470","47193700","69416"],"Wikipedia":["Ferulic_acid"],"drugbank":["DB07767"],"chEBI":["17620"]},"childChemblIds":["CHEMBL4594451"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL331373","canonicalSmiles":"O=CN(O)CC(=O)O","inchiKey":"URJHVPKUWOUENU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HADACIDIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Hadacidin"],"crossReferences":{"drugbank":["DB02109"],"chEBI":["43040"]},"childChemblIds":["CHEMBL2028418"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL340978","canonicalSmiles":"CC(C(=O)O)c1ccc2oc(-c3ccc(Cl)cc3)nc2c1","inchiKey":"MITFXPHMIHQXPI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BENOXAPROFEN","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"," United Kingdom"," United States"," Spain"," Germany"],"classes":["Carcinogenicity"," Dermatological toxicity"," Gastrotoxicity"," Hepatotoxicity"," Nephrotoxicity"],"year":1982},"tradeNames":["Oraflex"],"synonyms":["Benoxaprofen","COMPD 90459","COMPOUND 90459","Coxigon","NSC-299582","Opren"],"crossReferences":{"Wikipedia":["Benoxaprofen"],"drugbank":["DB04812"],"chEBI":["76114"]},"linkedTargets":{"rows":["ENSG00000108839"],"count":1},"linkedDiseases":{"rows":["EFO_0005755"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1982 and is indicated for rheumatic disease. It was withdrawn in United States,  United Kingdom,  United States,  Spain and  Germany initially in 1982 due to Carcinogenicity,  Dermatological toxicity,  Gastrotoxicity,  Hepatotoxicity and  Nephrotoxicity."}
{"id":"CHEMBL352418","canonicalSmiles":"O=C(O)[C@@H]1C[C@@H](O)CN1","inchiKey":"PMMYEEVYMWASQN-DMTCNVIQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL352418","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["100079"],"drugbank":["DB08847"],"chEBI":["18095"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3545078","drugType":"Small molecule","blackBoxWarning":false,"name":"PF-03814735","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PF 03814735","PF 3814735","PF-3814735","Pf-03814735"],"linkedTargets":{"rows":["ENSG00000087586","ENSG00000178999"],"count":2},"linkedDiseases":{"rows":["EFO_0000616"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3545225","drugType":"Small molecule","blackBoxWarning":false,"name":"INCB-047986","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Incb-047986","Incb-47986"],"linkedTargets":{"rows":["ENSG00000162434"],"count":1},"linkedDiseases":{"rows":["EFO_0000198","EFO_0000685","MONDO_0007254","EFO_0000183"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL3545316","drugType":"Antibody","blackBoxWarning":false,"name":"RINUCUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["REGN-2176","REGN2176","Rinucumab"],"linkedTargets":{"rows":["ENSG00000113721"],"count":1},"linkedDiseases":{"rows":["EFO_0001365"],"count":1},"description":"Antibody drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3545341","canonicalSmiles":"Cl.O=c1[nH]ccc2cc(OC3CCNCC3)ccc12","inchiKey":"KMNVOGVCCZNVNU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SAR-407899","maximumClinicalTrialPhase":2,"parentId":"CHEMBL1667969","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["SAR-407899","Sar-407899"],"linkedTargets":{"rows":["ENSG00000134318","ENSG00000067900"],"count":2},"linkedDiseases":{"rows":["EFO_0004234","EFO_0001645","EFO_0003884"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL3545389","drugType":"Small molecule","blackBoxWarning":false,"name":"LY2245461","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ly2245461"],"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL3545410","drugType":"Small molecule","blackBoxWarning":false,"name":"TC-6987","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["TC-6987","Tc-6987"],"linkedTargets":{"rows":["ENSG00000175344"],"count":1},"linkedDiseases":{"rows":["MONDO_0004979","MONDO_0005148"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3643413","canonicalSmiles":"CCC(=O)N1CC[C@H](Nc2ncnc3c2CN(c2cnc(OC)c(C(F)(F)F)c2)CC3)C1","inchiKey":"MWKYMZXCGYXLPL-ZDUSSCGKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LENIOLISIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CDZ-173-NX","CDZ173-NX","Cdz-173 free base","Cdz173 free base","Leniolisib"],"childChemblIds":["CHEMBL3989909"],"linkedTargets":{"rows":["ENSG00000171608"],"count":1},"linkedDiseases":{"rows":["Orphanet_397596","Orphanet_1572","EFO_0000699"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3707228","drugType":"Antibody","blackBoxWarning":false,"name":"PLOZALIZUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["HU-1D9","MLN-1202","MLN1202","Plozalizumab","hu1D9"],"linkedTargets":{"rows":["ENSG00000121807"],"count":1},"linkedDiseases":{"rows":["EFO_0003914","MONDO_0005301","EFO_0000756","EFO_0000401","EFO_0000319","MONDO_0024880"],"count":6},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL3989762","canonicalSmiles":"CC[C@H]1[C@H]2C[C@H]3[C@@H]4N(C)c5ccccc5[C@]45C[C@@H](C2[C@H]5OC(=O)CCl)N3[C@@H]1O","inchiKey":"LAHDERDHXJFFJU-RVPOWFKMSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LORAJMINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ajmaline 17-(chloroacetate)","Lorajmine"],"childChemblIds":["CHEMBL3989784"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3989763","canonicalSmiles":"CO[C@@H]1O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@@H](O[C@@H]3O[C@H](CO)[C@@H](O[C@@H]4O[C@H](CO)[C@@H](O[C@@H]5O[C@H](CO)[C@@H](O[C@@H]6O[C@H](C(=O)O)[C@@H](O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@H](CO)[C@@H](OC)[C@H](OC(C)=O)[C@@H]8O)[C@H](OC(C)=O)[C@@H]7O)[C@H](OC(C)=O)[C@@H]6O)[C@H](OC(C)=O)[C@@H]5O)[C@@H](O)[C@@H]4NC(C)=O)[C@H](OC(C)=O)[C@@H]3O)[C@H](OC(C)=O)[C@@H]2O)[C@H](OC(C)=O)[C@@H]1O","inchiKey":"XOYXESIZZFUVRD-YGGZJJQXSA-N","drugType":"Oligosaccharide","blackBoxWarning":false,"name":"ACEMANNAN","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Carraklenz wound & skin cleanser","Carrisyn","Snow & sun sports gel"],"synonyms":["Acemannan","Acemannan (aloe vera)","Acemannan aloe vera (1300000 mw)","Acemannan aloe vera (1400000 mw)","Cello gel","Polymannoacetate","Polymanoacetate"],"description":"Oligosaccharide drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3989872","canonicalSmiles":"C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@@]1(Cc1ccccc1)C(=O)N[C@H](C(N)=O)[C@@H](C)O","inchiKey":"DVBUEXCIEIAXPM-PJUQSVSOSA-N","drugType":"Protein","blackBoxWarning":false,"name":"APIMOSTINEL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Apimostinel","NRX-1074","Nrx-1074"],"crossReferences":{"drugbank":["DB11784"]},"linkedTargets":{"rows":["ENSG00000183454","ENSG00000273079","ENSG00000116032","ENSG00000161509","ENSG00000105464","ENSG00000176884","ENSG00000198785"],"count":7},"linkedDiseases":{"rows":["MONDO_0005090","MONDO_0002009"],"count":2},"description":"Protein drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL3990046","drugType":"Gene","blackBoxWarning":false,"name":"ELIVALDOGENE TAVALENTIVEC","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Elivaldogene tavalentivec","Lenti-D","Lenti-D Drug Product"],"description":"Gene drug with a maximum clinical trial phase of II (across all indications) and has 16 investigational indications."}
{"id":"CHEMBL4098253","canonicalSmiles":"COC1CCN(C(=O)c2cc(Cc3n[nH]c(=O)c4ccccc34)ccc2F)CC1","inchiKey":"HYNBNUYQTQIHJK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AZD2461","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Azd2461"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4101487","canonicalSmiles":"O=C(O)c1ccc([C@H]2C[C@@H](NC(=O)C3(c4ccc5c(c4)OC(F)(F)O5)CC3)c3ccc(OC(F)F)cc3O2)cc1","inchiKey":"QVDYQHXNAQHIKH-TZIWHRDSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GALICAFTOR","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ABBV-2222","GLPG-2222","GLPG2222","Galicaftor","Glpg2222"],"crossReferences":{"drugbank":["DB14894"]},"linkedTargets":{"rows":["ENSG00000001626"],"count":1},"linkedDiseases":{"rows":["Orphanet_586"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL418471","canonicalSmiles":"CCNC(=O)/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C","inchiKey":"WKYDOCGICAMTKE-NBIQJRODSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL418471","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03917"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4297186","canonicalSmiles":"CN(C)Cc1ccc(CSCCNC(=C[N+](=O)[O-])NCc2ccc3c(c2)OCO3)o1","inchiKey":"HXRSXEDVVARPHP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NIPEROTIDINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Niperotidine"],"crossReferences":{"drugbank":["DB13760"]},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297187","canonicalSmiles":"COCCNCCc1cccc(Nc2ncc3c(n2)-c2ccccc2[C@H](c2ccccc2F)C3)c1","inchiKey":"KPJDVVCDVBFRMU-AREMUKBSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DERAZANTINIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ARQ 087","ARQ087","Arq-087","Derazantinib"],"crossReferences":{"drugbank":["DB14889"]},"childChemblIds":["CHEMBL4298156"],"linkedTargets":{"rows":["ENSG00000066468","ENSG00000068078","ENSG00000077782","ENSG00000160867"],"count":4},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000503","EFO_0008528","EFO_1001961"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4297287","canonicalSmiles":"COc1ccc([C@H]2CNC(=O)[C@H](Cc3cccc(C)c3)C2)cc1OC1CCCC1","inchiKey":"ABEJDMOBAFLQNJ-NHCUHLMSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HT-0712","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BLX-028914","Blx-028914","Ht-0712","IPL-455903","OX-914"],"crossReferences":{"drugbank":["DB11650"]},"linkedTargets":{"rows":["ENSG00000065989","ENSG00000105650","ENSG00000113448","ENSG00000184588"],"count":4},"linkedDiseases":{"rows":["EFO_0005854","EFO_0001072"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297305","canonicalSmiles":"Nc1ncnc2c1ncn2CCNCCCCCO","inchiKey":"CVPTTZZCRDVGSU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NB-001","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["HTS-09836","NB001","Nb-001"],"crossReferences":{"drugbank":["DB12716"]},"description":"Small molecule drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4297311","canonicalSmiles":"COc1cc(Cl)ccc1[C@H]1c2[nH]c3cccc(F)c3c2C2(CC2)CN1C(C)=O","inchiKey":"ZBQMTQGDBFZUBG-NRFANRHFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ONO-2952","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ono-2952"],"crossReferences":{"drugbank":["DB14802"]},"linkedTargets":{"rows":["ENSG00000100300"],"count":1},"linkedDiseases":{"rows":["EFO_0000555"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4297429","canonicalSmiles":"C[C@H](O)[C@@H](O)[C@@H](O)[C@H](F)C=O","inchiKey":"SQTFKIKSQNCWGJ-KCDKBNATSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"2-FLUOROFUCOSE","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["2-fluorofucose","Sgn-2ff"],"crossReferences":{"drugbank":["DB15302"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4297449","canonicalSmiles":"CC(C)N1CCC(N2CCCN(c3cccc(C(=O)Nc4ccncc4)n3)CC2)CC1","inchiKey":"XNUNVQKARNSSEO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"USL-311","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["USL311","Usl 311","Usl-311","Usl311"],"crossReferences":{"drugbank":["DB15265"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297462","canonicalSmiles":"COc1ccc2c(c1)[C@]1(C[C@H]1c1ccc3c(/C=C/c4ccc(CN5C[C@H](C)O[C@H](C)C5)cc4)n[nH]c3c1)C(=O)N2.O=C(O)/C=C/C(=O)O","inchiKey":"AQCDFVLWUWJREO-WQVJSASDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CFI-400945","maximumClinicalTrialPhase":2,"parentId":"CHEMBL3408947","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CFI-400945","CFI-400945 FUMARATE","Cfi 400945","Cfi-400945","Cfi-400945 fumarate"],"linkedTargets":{"rows":["ENSG00000142731"],"count":1},"linkedDiseases":{"rows":["MONDO_0007254","MONDO_0008315","EFO_0000311"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4297613","canonicalSmiles":"O=C(O)c1ccnc(N2CC(O)(c3ccc(OCc4c(-c5c(Cl)cccc5Cl)noc4C4CC4)cc3Cl)C2)c1","inchiKey":"KZSKGLFYQAYZCO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CILOFEXOR","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cilofexor","GS 9674","GS-9674","Gs-9674","PX-104","PX104"],"crossReferences":{"drugbank":["DB15168"]},"linkedTargets":{"rows":["ENSG00000012504"],"count":1},"linkedDiseases":{"rows":["EFO_0004268","EFO_1001249","EFO_1001486"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4297640","canonicalSmiles":"NC(=O)[C@H]1CCN(c2ncnc(N)c2F)C[C@@H]1N1CCC[C@@H](Nc2cc(Cl)cc(C(F)(F)F)c2)C1=O","inchiKey":"QLRRJMOBVVGXEJ-XHSDSOJGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"VECABRUTINIB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["BIIB-062","BSK-4841","FP-0182","FP0182","SNS-062","Sns-062","Vecabrutinib"],"childChemblIds":["CHEMBL4298148"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4297756","drugType":"Antibody","blackBoxWarning":false,"name":"FREMANEZUMAB","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ajovy"],"synonyms":["Fremanezumab","Fremanezumab-vfrm","LBR-101","LBR101","PF-04472429","PF04472429","RN-307","RN307","TEV-48125","TEV48125","Tev-48125"],"crossReferences":{"DailyMed":["fremanezumab-vfrm"]},"linkedTargets":{"rows":["ENSG00000110680","ENSG00000175868"],"count":2},"linkedDiseases":{"rows":["MONDO_0005277","EFO_0005687","EFO_0008507","EFO_0003843"],"count":4},"description":"Antibody drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2018 and is indicated for migraine disorder and has 3 investigational indications."}
{"id":"CHEMBL4297792","drugType":"Unknown","blackBoxWarning":false,"name":"MYRCLUDEX B","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Hbvpres2-48myr","Myrcludex b"],"description":"Unknown drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL4297921","drugType":"Small molecule","blackBoxWarning":false,"name":"CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED)","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Carbomer homopolymer type b","Carbomer homopolymer type b (allyl pentaerythritol crosslinked)","Carbopol 974"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297965","drugType":"Unknown","blackBoxWarning":false,"name":"GSK-1614235","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["DSP-3235","DSP-3235 SEBACATE","GSK-1614235","GSK-16142353 SEBACATE","GSK1614235","Gsk-1614235","Gsk1614235","KGA-3235","KGA-3235 SEBACATE","KWA-0711 SEBACATE","Mizagliflozin sebacate"],"description":"Unknown drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4298010","drugType":"Enzyme","blackBoxWarning":false,"name":"VELMANASE ALFA","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Lamazym","Lamzede","R-h-laman","Recombinant human laman","Rhlaman","Velmanase alfa"],"description":"Enzyme drug with a maximum clinical trial phase of IV and has 1 investigational indication."}
{"id":"CHEMBL4303187","canonicalSmiles":"CN(C)c1cccc(-c2c3c(=O)n(-c4ccccc4Cl)[nH]c3cc(=O)n2C)c1","inchiKey":"RGYQPQARIQKJKH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SETANAXIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GKT-137831","GKT-831","Setanaxib"],"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL442218","canonicalSmiles":"O=C1N[C@H](C(=O)O)CS1","inchiKey":"BMLMGCPTLHPWPY-REOHCLBHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PROCYSTEINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Koprosteine","L-2-oxo-4-thiazolidinecarboxylic acid","Oxothiazolidinecarboxylic acid","Procysteine"],"crossReferences":{"drugbank":["DB12224"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL443014","canonicalSmiles":"COC(COC(N)=O)C1=C(N2CC2)C(=O)C(C)=C(N2CC2)C1=O","inchiKey":"SHHKQEUPHAENFK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CARBOQUONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Carboquone","Esquinon"],"crossReferences":{"PubChem":["144206299","423331","92763414"],"drugbank":["DB13677"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL447","canonicalSmiles":"C=CCC1(C(C)CCC)C(=O)NC(=O)NC1=O","inchiKey":"KQPKPCNLIDLUMF-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SECOBARBITAL","yearOfFirstApproval":1950,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["France"," Norway"],"classes":["Misuse"],"year":1980},"tradeNames":["Seconal"],"synonyms":["(rs)-secobarbital","Evronal","Hypotrol","Immenox","Meballymal","Quinalbarbital","Secobarbital","Secobarbital cii","Secobarbital sodium free acid","Secobarbitone","Somatarax"],"crossReferences":{"Wikipedia":["Secobarbital"],"drugbank":["DB00418"],"chEBI":["9073"]},"childChemblIds":["CHEMBL1200903"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1950. It was withdrawn in France and  Norway initially in 1980 due to Misuse."}
{"id":"CHEMBL4594241","drugType":"Small molecule","blackBoxWarning":false,"name":"TECHNETIUM TC 99M SESTAMIBI","yearOfFirstApproval":1990,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL4594619","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cardiolite","Miraluma","Technetium tc 99m sestamibi","Technetium tc-99m sestamibi"],"synonyms":["Sestamibi","TC99M RP-30A","TC99M-RP-30A","Technetium (99m tc) sestamibi","Technetium (99mtc) sestamibi","Technetium tc 99m sestamibi","Technetium tc-99m sestamibi kit"],"crossReferences":{"DailyMed":["technetium%20tc-99m%20sestamibi%20kit"]},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1990 and is indicated for coronary artery disease."}
{"id":"CHEMBL4594338","drugType":"Oligonucleotide","blackBoxWarning":false,"name":"NEDOSIRAN SODIUM","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["DCR-PHXC","Dcr-phxc","Nedosiran sodium"],"linkedTargets":{"rows":["ENSG00000134333"],"count":1},"linkedDiseases":{"rows":["Orphanet_416","Orphanet_93599","Orphanet_93598","Orphanet_93600"],"count":4},"description":"Oligonucleotide drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4594359","drugType":"Unknown","blackBoxWarning":false,"name":"PALTUSOTINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Paltusotine"],"description":"Unknown drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL46294","canonicalSmiles":"Nc1nc(=O)c2c([nH]1)NCC(CNc1ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)cc1)=N2","inchiKey":"OZRNSSUDZOLUSN-LBPRGKRZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIHYDROFOLIC ACID","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Dihydrofolic acid"],"crossReferences":{"Wikipedia":["Dihydrofolic_acid"],"drugbank":["DB02015"],"chEBI":["15633"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL4650480","drugType":"Antibody","blackBoxWarning":false,"name":"BARECETAMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Barecetamab","ISU-104","ISU104","Isu104"],"description":"Antibody drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL46917","canonicalSmiles":"CNC(=O)Oc1cccc2ccccc12","inchiKey":"CVXBEEMKQHEXEN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CARBARIL","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Carylderm","Clinicide","Derbac","Derbac-c","Suleo-c"],"synonyms":["Carbaril","Carbaryl","ENT-23969","NSC-27311"],"crossReferences":{"PubChem":["144204545","144209034","144211171","170465695","17389992","26730497","26752735","50105386"],"Wikipedia":["Carbaryl"],"chEBI":["3390"]},"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL473417","canonicalSmiles":"CS(=O)(=O)c1ccc(C(=O)Nc2ccc(Cl)c(-c3ccccn3)c2)c(Cl)c1","inchiKey":"BPQMGSKTAYIVFO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"VISMODEGIB","yearOfFirstApproval":2012,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Erivedge"],"synonyms":["GDC-0449","NSC-747691","NSC-755986","Vismodegib"],"crossReferences":{"DailyMed":["vismodegib"],"drugbank":["DB08828"],"chEBI":["66903"]},"childChemblIds":["CHEMBL4129312","CHEMBL4125998","CHEMBL4127241"],"linkedTargets":{"rows":["ENSG00000128602"],"count":1},"linkedDiseases":{"rows":["MONDO_0018648","MONDO_0013730","EFO_0003897","EFO_0000616","EFO_0002618","MONDO_0044903","EFO_0000768","MONDO_0008170","EFO_1001465","MONDO_0007254","MONDO_0005341","EFO_0000222","EFO_0002939","EFO_0000305","MONDO_0008315","EFO_0000311","EFO_1001480","EFO_1000044","Orphanet_377","EFO_0002517","EFO_0000673","EFO_0000326","EFO_0000702","EFO_0001378","EFO_0004193","Orphanet_2495","EFO_0000519"],"count":27},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2012 and has 4 approved and 20 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL495224","canonicalSmiles":"N[C@@H](CCCO)C(=O)O","inchiKey":"CZWARROQQFCFJB-BYPYZUCNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"L-5-Hydroxynorvaline","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["L-5-Hydroxynorvaline"],"crossReferences":{"drugbank":["DB03105"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL497939","canonicalSmiles":"O=c1cccc2n1C[C@@H]1CNC[C@H]2C1","inchiKey":"ANJTVLIZGCUXLD-DTWKUNHWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CYTISINICLINE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Tabex"],"synonyms":["6039 Sopharma","Baptitoxine","Cytisine","Cytisinicline","Cytiton","NSC-407282","Sophorine","Ulexine"],"crossReferences":{"PubChem":["11112361","11114058","26752181","477069","56463106"],"Wikipedia":["Cytisine"],"drugbank":["DB09028"],"chEBI":["4055"]},"linkedTargets":{"rows":["ENSG00000160716","ENSG00000101204"],"count":2},"linkedDiseases":{"rows":["EFO_0004319","EFO_0003768"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL502182","canonicalSmiles":"COc1cccc(-c2c(C)n(Cc3c(F)cccc3C(F)(F)F)c(=O)n(C[C@H](NCCCC(=O)[O-])c3ccccc3)c2=O)c1F.[Na+]","inchiKey":"DQYGXRQUFSRDCH-UQIIZPHYSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"ELAGOLIX SODIUM","yearOfFirstApproval":2018,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1208155","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Orilissa"],"synonyms":["Elagolix sodium","Elagolix sodium salt","NBI-56418 NA","NBI-56418-NA","Orlissa"],"crossReferences":{"DailyMed":["elagolix%20sodium"]},"linkedTargets":{"rows":["ENSG00000109163"],"count":1},"linkedDiseases":{"rows":["EFO_0001065"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2018 and is indicated for endometriosis."}
{"id":"CHEMBL50514","canonicalSmiles":"COc1cc(N(C)Cc2cnc3nc(N)nc(N)c3c2C)cc(OC)c1OC","inchiKey":"PEGMMEYCSOZKIT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL50514","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02104"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL513425","canonicalSmiles":"N[C@@H](CC(=O)N1CCCCCN1C(=O)c1ccccc1)Cc1cc(F)c(F)cc1F","inchiKey":"XXRHRPGYYNOBHO-QGZVFWFLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL513425","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08051"]},"childChemblIds":["CHEMBL539611"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL540","canonicalSmiles":"c1c[nH]cn1","inchiKey":"RAXXELZNTBOGNW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IMIDAZOLE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Imidazole"],"crossReferences":{"PubChem":["144208702","17388974"],"Wikipedia":["Imidazole"],"drugbank":["DB03366"],"chEBI":["16069"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL56337","canonicalSmiles":"CC(/C=C1\\SC(=S)N(CC(=O)O)C1=O)=C\\c1ccccc1","inchiKey":"CHNUOJQWGUIOLD-NFZZJPOKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EPALRESTAT","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Aldonil","Aldorin","Epalrestat","Kinedak","Tanglin"],"crossReferences":{"PubChem":["26664249","26758035"],"Wikipedia":["Epalrestat"],"drugbank":["DB15293"],"chEBI":["31539"]},"childChemblIds":["CHEMBL4297277"],"linkedTargets":{"rows":["ENSG00000085662"],"count":1},"linkedDiseases":{"rows":["EFO_1000783","Orphanet_79318","MONDO_0007254","EFO_0000400"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL66092","canonicalSmiles":"CCN(C(=O)c1c(O)c2c(Cl)cccc2n(C)c1=O)c1ccccc1","inchiKey":"GKWPCEFFIHSJOE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LAQUINIMOD","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ABR-215062","ABR-215062 FREE ACID","Laquinimod","TV-5600 FREE ACID"],"crossReferences":{"PubChem":["174007071"],"Wikipedia":["Laquinimod"],"drugbank":["DB06685"]},"childChemblIds":["CHEMBL2103814"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL73303","canonicalSmiles":"NS(=O)(=O)c1ccc(Nc2nccc(-c3cnc4ccccn34)n2)cc1","inchiKey":"NKORVPQBJCGYEC-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL73303","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB02197"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL812","canonicalSmiles":"CN(C)C(=O)Oc1ccc[n+](C)c1.[Br-]","inchiKey":"VNYBTNPBYXSMOO-UHFFFAOYSA-M","drugType":"Small molecule","blackBoxWarning":true,"name":"PYRIDOSTIGMINE BROMIDE","yearOfFirstApproval":1955,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1115","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Kalymin","Mestinon","Mestinon 10","Mestinon ret","Pyridostigmine bromide","Regonal","Regonol"],"synonyms":["Kalimin","Kalymin","NSC-679759","NSC-758435","Pyridostigmine Bromide","Pyridostigmine bromide","Pyridostigmini bromidum","RO-1-5130"],"crossReferences":{"DailyMed":["pyridostigmine%20bromide"],"PubChem":["144204818","170464878","26747656","50106936","518187","56422100","855974"]},"linkedTargets":{"rows":["ENSG00000087085"],"count":1},"linkedDiseases":{"rows":["Orphanet_365","Orphanet_93961","MONDO_0100096","EFO_0003144","MONDO_0005180","EFO_0005252","EFO_0004991","EFO_0005251"],"count":8},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1955 and is indicated for myasthenia gravis and has 6 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL86554","canonicalSmiles":"CCCCCCCC/C=C/CCCCCCCC(N)=O","inchiKey":"FATBGEAMYMYZAF-MDZDMXLPSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL86554","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03784"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL87697","canonicalSmiles":"N#Cc1ccccc1OCC(O)CNCCNC(=O)Cc1ccc(O)cc1","inchiKey":"YARKMNAWFIMDKV-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"EPANOLOL","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Epanolol","ICI 141,292","ICI-141292"],"crossReferences":{"drugbank":["DB13757"],"chEBI":["4800"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
